Page last updated: 2024-12-08

propargylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

propargylamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID239041
CHEMBL ID3263480
MeSH IDM0053435

Synonyms (46)

Synonym
prop-2-ynylamine
3-aminopropyne
wln: z2uu1
2-propynylamine
propargylamine
2450-71-7
nsc80642
nsc-80642
2-propyn-1-amine
propargylamine, 98%
jkanavgodyycqf-uhfffaoysa-
inchi=1/c3h5n/c1-2-3-4/h1h,3-4h2
prop-2-yn-1-amine
3-amino-1-propyne
P0911
AKOS000121278
n-(2-propyn-1-yl)amine
3-aminoprop-1-yne
BP-13342
FT-0613387
STL372726
RB8001
CHEMBL3263480
BBL027696
2-propyn-1-ylamine
prop-2-ynyl-amine
mono-propargyl amine
propargylamin
propargyl amine
monopropargylamine
pro-pargylamine
amino-2-propyne
AM86798
Q-200322
1-propine, 3-amino-
mono-propargylamine
F0001-0832
propargylamine, purum, >=98.0% (gc)
mfcd00008198
J-015548
DTXSID30862951
Q27465112
CS-0015258
STR01139
BP-31099
EN300-21409

Research Excerpts

Overview

Propargylamine is a chemical moiety whose properties have made it a widely distributed group within the fields of medicinal chemistry and chemical biology.

ExcerptReferenceRelevance
"Propargylamine is a chemical moiety whose properties have made it a widely distributed group within the fields of medicinal chemistry and chemical biology. "( Propargylamine: an important moiety in drug discovery.
Borges, F; Carneiro, A; Matos, MJ; Uriarte, E, 2023
)
3.8

Effects

ExcerptReferenceRelevance
"Propargylamines have been demonstrated to be potent anti-apoptotic agents in both in vitro and in vivo studies, presumably by maintaining glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a dimer and thereby preventing its nuclear translocation where it blocks upregulation of anti-apoptotic proteins."( Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Olanow, CW, 2006
)
1.34

Toxicity

ExcerptReferenceRelevance
"The ability of allylamine (AA) administration to produce vascular lesions resembling atherosclerotic disease in animals, has been linked to metabolism of AA to the toxic aldehyde acrolein (ACR) by a semicarbazide-sensitive amine oxidase (SSAO) found in plasma and in vascular smooth muscle."( [Effect of activity of semicarbazide-sensitive aminooxidases and cellular glutathione on the cytotoxic effect of allylamine, acrolein, and formaldehyde in human cultured endothelial cells].
Lyles, GA; Pino, R,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1141991Inhibition of NMDA receptor in Wistar rat brain synaptoneurosomes homogenate assessed as calcium flux at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID1141989Antiapoptotic activity against serum deprivation-induced human SK-N-BE(2) cells assessed as viable cells at 10 uM after 36 hrs incubation by DePsipher agent relative to control2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID1141990Inhibition of voltage gated calcium channel in Wistar rat brain synaptoneurosomes homogenate assessed as intracellular calcium at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID1141992Inhibition of MAO-B in baboon liver mitochondrial fraction using MPTP substrate at 300 uM2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (198)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.52)18.7374
1990's9 (4.55)18.2507
2000's67 (33.84)29.6817
2010's91 (45.96)24.3611
2020's28 (14.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.29 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index70.61 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews21 (10.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other186 (89.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]